Therefore, blockade of IFN-γ signalling or those metabolic processes, and application of those small inhibitors may synergize with anti-CEACAM5 antibodies to improve the elimination of immune evasion in stemness-high pancreatic cancers. The gene discussed is CEACAM5; the disease is pancreatic neoplasm.